Unmet Needs in Managing Hypertension: Potential Role of Direct Renin Inhibition

References

• . Chobanian AV, Bakris GL, Black HR, . Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41(6):1341–1345
   PubMed Web of Science ®Google Scholar
• . Lloyd-Jones D, Adams R, Carnethon M, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–e181
   PubMed Web of Science ®Google Scholar
• . Fox CS, Muntner P. Trends in diabetes, high cholesterol, and hypertension in chronic kidney disease among U.S. adults: 1988–1994 to 1999–2004. Diabetes Care. 2008;31(7):1337–1342
   PubMed Web of Science ®Google Scholar
• . Cirillo M, Lanti MP, Menotti A, . Definition of kidney dysfunction as a cardiovascular risk factor: use of urinary albumin excretion and estimated glomerular filtration rate. Arch Intern Med. 2008;168(6):617–624
   PubMedGoogle Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar
• . Beckett NS, Peters R, Fletcher AE, ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–1898
   PubMed Web of Science ®Google Scholar
• . Dahlof B, Sever PS, Poulter NR, . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906
   PubMed Web of Science ®Google Scholar
• . Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279–1283
   PubMed Web of Science ®Google Scholar
• . Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9(6):324–332
   PubMedGoogle Scholar
• . Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9( 9 suppl):2–6
   PubMedGoogle Scholar
• . Jamerson K, Weber MA, Bakris GL, . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428
   PubMed Web of Science ®Google Scholar
• . Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation. 2009;119(3):371–373
   PubMed Web of Science ®Google Scholar
• . Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75
   PubMed Web of Science ®Google Scholar
• . Saydah S, Fradkin J, Cowie C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291(3):335–342
   PubMed Web of Science ®Google Scholar
• . Plantinga L, Miller ER 3rd, Stevens L, ; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease. Hypertension. 2009;54(1):47–56
   PubMed Web of Science ®Google Scholar
• . Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 suppl B):9–20
   PubMed Web of Science ®Google Scholar
• . Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov. 2008;7(5):399–410
   PubMed Web of Science ®Google Scholar
• . Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637–645
   PubMed Web of Science ®Google Scholar
• . Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens. 2006;15(5):505–510
   PubMed Web of Science ®Google Scholar
• . Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39(1):E1–E8
   PubMed Web of Science ®Google Scholar
• . Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens. 2003;16(5 pt 1):407–415
   PubMed Web of Science ®Google Scholar
• . Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens. 1997;10(1):1–8
   PubMed Web of Science ®Google Scholar
• . Campbell DJ, Woodward M, Chalmers JP, . Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation. 2005;112(1):110–116
   PubMed Web of Science ®Google Scholar
• . Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8):1012–1018
   PubMed Web of Science ®Google Scholar
• . Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49(11):1157–1163
   PubMed Web of Science ®Google Scholar
• . Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370(9583):221–229
   PubMed Web of Science ®Google Scholar
• . Pool JL, Schmieder RE, Azizi M, . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11–20
   PubMed Web of Science ®Google Scholar
• . Villamil A, Chrysant SG, Calhoun D, . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25(1):217–226
   PubMed Web of Science ®Google Scholar
• . Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42(6):1137–1143
   PubMed Web of Science ®Google Scholar
• . Schmieder RE, Philipp T, Guerediaga J, . Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119(3):417–425
   PubMed Web of Science ®Google Scholar
• . Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich). 2007;9(10):742–750
   PubMedGoogle Scholar
• . Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens. 2007;20(5):587–597
   PubMed Web of Science ®Google Scholar
• . Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension. 2008;51(1):15–18
   PubMed Web of Science ®Google Scholar
• . Danser AJ. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? [published online ahead of print]. Hypertens Res.
   Google Scholar
• . Stanton AV, Gradman AH, Schmieder RE, Nussberger J, Sarangapani R, Prescott MF. Aliskiren monotherapy does not cause paradoxical blood pressure rises. Meta-analysis of data from 8 clinical trials. Hypertension. 2010;55(1):54–60
   PubMed Web of Science ®Google Scholar
• . Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens. 2009;22(9):954–957
   PubMed Web of Science ®Google Scholar
• . Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens. 2009;22(1):112–121
   PubMed Web of Science ®Google Scholar
• . Gradman AH, Traub D. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension. Rev Cardiovasc Med. 2007;8( suppl 2):S22–S30
   Web of Science ®Google Scholar
• . Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens. 2007;1(4):264–277
   PubMed Web of Science ®Google Scholar
• . Frishman WH, Ram CV, McMahon FG, . Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol. 1995;35(11):1060–1066
   PubMed Web of Science ®Google Scholar
• . Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol. 2000;86(11):1182–1187
   PubMed Web of Science ®Google Scholar
• . Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004;17(6):495–501
   PubMed Web of Science ®Google Scholar
• . Venzin RM, Cohen CD, Maggiorini M, Wuthrich RP. Aliskiren-associated acute renal failure with hyperkalemia. Clin Nephrol. 2009;71(3):326–328
   PubMed Web of Science ®Google Scholar
• . Vasan RS, Beiser A, Seshadri S, . Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003–1010
   PubMed Web of Science ®Google Scholar
• . Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial [published online ahead of print December 24, 2009]. J Hum Hypertens.
   Google Scholar
• . Bramlage P, Pittrow D, Wittchen HU, . Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17(10):904–910
   PubMed Web of Science ®Google Scholar
• . Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007;49(5):1047–1055
   PubMed Web of Science ®Google Scholar
• . Uresin Y, Taylor AA, Kilo C, . Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190–198
   PubMed Web of Science ®Google Scholar
• . Imanishi T, Tsujioka H, Ikejima H, . Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52(3):563–572
   PubMed Web of Science ®Google Scholar
• . KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12–154
   PubMed Web of Science ®Google Scholar
• . Price DA, Porter LE, Gordon M, . The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10(11):2382–2391
   PubMed Web of Science ®Google Scholar
• . Yamamoto T, Nakagawa T, Suzuki H, . Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007;18(5):1558–1565
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Persson F, Rossing P, Reinhard H, . Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32(10):1873–1879
   PubMed Web of Science ®Google Scholar
• . Verdeecchia P, Carini G, Circo A, ; MAVI Study Group. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI Study. J Am Coll Cardiol. 2001;38(7):1829–1835
   PubMed Web of Science ®Google Scholar
• . Devereux R, Okin P, Roman M. Left ventricular hypertrophy as a surrogate endpoint in hypertension. Clin Exp Hypertens. 1999;21(5–6):583–593
   PubMed Web of Science ®Google Scholar
• . Solomon SD, Appelbaum E, Manning WJ, . Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–537
   PubMed Web of Science ®Google Scholar
• . McMurray JJ, Pitt B, Latini R, . Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1(1):17–24
   PubMed Web of Science ®Google Scholar
• . Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004;90(3):297–303
   PubMed Web of Science ®Google Scholar
• . Latini R, Masson S, Anand I, ; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25(4):292–299
   PubMed Web of Science ®Google Scholar
• . Parving HH, Brenner BM, McMurray JJ, . Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663–1671
   PubMed Web of Science ®Google Scholar
• . Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3(9):486–492
   PubMedGoogle Scholar